ReviewPathologica2022
Adult type diffuse gliomas in the new 2021 WHO Classification.
Review in Pathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Performance of Artificial Intelligence in Classifying Molecular Markers in Adult-Type Gliomas Using Histopathological Images: Systematic Review.Journal of medical Internet research · 2026Pooled it
- Radiotherapy for High-Grade Gliomas in Adults and Children: A Systematic Review of Advances Published in the Second Half of 2023.International journal of molecular sciences · 2026Pooled it
- Review
- GLUD1 Inhibition Disrupts Glutamate Homeostasis and Induces Metabolic and Redox Stress in Gliomas.Cells · 2026Article
- Status and trends in glioblastoma lipid metabolism research: a bibliometric analysis.Discover oncology · 2026Review
- Article
- Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target.Pharmacological reports : PR · 2026Review
- Histological grade 2 and non-contrast-enhancing phenotype provide prognostic information complementary to DNA methylation classification in TERTp-mutant molecular glioblastomas.Acta neuropathologica communications · 2026Article
- Seizure Presentation of a Grade II Astrocytoma in a Patient With Ollier's Disease: A Case Report and Brief Review.Cureus · 2026Article
- Glioblastoma as a neuro-immune network disorder: rethinking the tumor microenvironment, neural circuit integration, and therapeutic resistance.Oncology reviews · 2026Review
- MRI-derived habitat heterogeneity for overall survival risk stratification in IDH-wildtype, CNS WHO grade 4 glioblastoma.Frontiers in cell and developmental biology · 2026Article
- An intra-axial wolf in extra-axial clothing: A rare case of high-grade astrocytoma and literature review.Surgical neurology international · 2026Article
- Radiomics-based machine learning for glioma grade classification: a multicenter study with SHapley Additive exPlanations interpretability analysis.Translational cancer research · 2025Article
- RadGLO: an interactive platform for radiomic feature analysis and prognostic modeling in glioma.NPJ precision oncology · 2025Article
- A high-grade glioma metastasis to the thoracic spine: illustrative case and a brief review.Discover oncology · 2025Article
- Liposomal Co-Delivery of Acteoside, CBD, and Naringenin: A Synergistic Strategy Against Gliomas.Pharmaceutics · 2025Article
- Impact of gastrointestinal dysbiosis on tryptophan metabolism and neurological cancer progression.Medical oncology (Northwood, London, England) · 2025Review
- Towards non-invasive diagnosis of glioblastoma: identifying metabolic biomarkers in liquid biopsies using a ROC-based approach.Discover oncology · 2025Article
- Review
- Mediation Mendelian randomization analysis of immune cell phenotypes and glioma risk: unveiling the regulation of cerebrospinal fluid metabolites.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-type diffuse gliomas represent a group of highly infiltrative central nervous system tumors with a prognosis that significantly varies depending on the specific subtype and histological grade. Traditionally, adult-type diffuse gliomas have been classified based on their morphological features with a great interobserver variability and discrepancy in patient survival even within the same histological grade. Over the last few decades, advances in molecular profiling have drastically changed the diagnostic approach and classification of brain tumors leading to the development of an integrated morphological and molecular classification endowed with a more clinically relevant value. These concepts were largely anticipated in the revised fourth-edition of WHO classification of central nervous system tumors published in 2016. The fifth-edition (WHO 2021) moved molecular diagnostics forward into a full integration of molecular parameters with the histological features into an integrative diagnostic approach. Diagnosis of adult type diffuse gliomas, IDH mutant and IDH-wildtype has been simplified by introducing revised diagnostic and grading criteria. In this review, we will discuss the most recent updates to the classification of adult-type diffuse gliomas and summarize the essential diagnostic keys providing a practical guidance to pathologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.